iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/21371012
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Oct;164(4):1079-106.
doi: 10.1111/j.1476-5381.2011.01302.x.

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)

Cris S Constantinescu  1 , Nasr Farooqi, Kate O'Brien, Bruno Gran
Affiliations
Review

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)

Cris S Constantinescu et al. Br J Pharmacol. 2011 Oct.

Abstract

Experimental autoimmune encephalomyelitis (EAE) is the most commonly used experimental model for the human inflammatory demyelinating disease, multiple sclerosis (MS). EAE is a complex condition in which the interaction between a variety of immunopathological and neuropathological mechanisms leads to an approximation of the key pathological features of MS: inflammation, demyelination, axonal loss and gliosis. The counter-regulatory mechanisms of resolution of inflammation and remyelination also occur in EAE, which, therefore can also serve as a model for these processes. Moreover, EAE is often used as a model of cell-mediated organ-specific autoimmune conditions in general. EAE has a complex neuropharmacology, and many of the drugs that are in current or imminent use in MS have been developed, tested or validated on the basis of EAE studies. There is great heterogeneity in the susceptibility to the induction, the method of induction and the response to various immunological or neuropharmacological interventions, many of which are reviewed here. This makes EAE a very versatile system to use in translational neuro- and immunopharmacology, but the model needs to be tailored to the scientific question being asked. While creating difficulties and underscoring the inherent weaknesses of this model of MS in straightforward translation from EAE to the human disease, this variability also creates an opportunity to explore multiple facets of the immune and neural mechanisms of immune-mediated neuroinflammation and demyelination as well as intrinsic protective mechanisms. This allows the eventual development and preclinical testing of a wide range of potential therapeutic interventions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic diagram of some of the key pathological features of EAE pathogenesis. Activated Th1 cells and Th17 cells are thought to be the main culprit in EAE and MS. Th1 are IFN-γ producing, and Th17 are IL-17 producing T lymphocytes. They are primed outside the CNS by dendritic cells, then cross the blood–brain barrier and encounter CNS antigen-presenting cells. They produce inflammatory products and cytokines that damage the myelin and axons. They also activate the resident microglia and produce factors that attract further inflammatory cells to the CNS and perpetuate the inflammatory cascade. Antibodies and B cells can also enter the CNS, and plasma cells produce antibodies within the CNS. Antibody mediated damage contributes to the inflammatory demyelination and neurodegeneration.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abreu SL. Suppression of experimental allergic encephalomyelitis by interferon. Immunol Commun. 1982;11:1–7. - PubMed
    1. Abreu SL, Thampoe I, Kaplan P. Interferon in experimental autoimmune encephalomyelitis: intraventricular administration. J Interferon Res. 1986;6:627–632. - PubMed
    1. Achiron A, Margalit R, Hershkoviz R, Markovits D, Reshef T, Melamed E, et al. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest. 1994;93:600–605. - PMC - PubMed
    1. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology. 1998;50:398–402. - PubMed
    1. Achiron A, Mor F, Margalit R, Cohen IR, Lider O, Miron S. Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins. J Autoimmun. 2000;15:323–330. - PubMed

Publication types